Preferred Label : Anti-CD137/PD-L1 Bispecific Antibody FS222;
NCIt synonyms : Anti-PD-L1/Anti-4-1BB Bispecific Antibody FS222; Anti-CD137/Anti-PD-L1 Bispecific Antibody FS222; CD137xPD-L1 Bispecific Antibody FS222;
NCIt definition : A tetravalent immunoglobulin G1 (IgG1) bispecific antibody targeting both the human
programmed death-ligand 1 (PD-L1) and CD137 (4-1BB; tumor necrosis factor receptor
superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating
and antineoplastic activities. Upon administration, anti-CD137/PD-L1 bispecific antibody
FS222 simultaneously targets and binds to CD137, which is expressed on a variety of
leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor
cells, thereby crosslinking PD-L1-expressing tumor cells and T-lymphocytes. Through
CD137 binding, FS222 acts as a conditional CD137 agonist, resulting in T-cell co-stimulation
and enhanced anti-tumor activity. At the same time, FS222 prevents PD-L1 from binding
to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed
death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes
and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction
in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion
and survival of CD8-positive T-cells, suppresses the immune system and results in
immune evasion. CD137, a surface glycoprotein of the tumor necrosis factor receptor
superfamily, is an inducible costimulatory receptor that plays a key role in T-cell
proliferation, survival and cytolytic activity. Crosslinking of PD-L1-expressing tumor
cells and activated T-lymphocytes may enhance T-lymphocyte-mediated lysis of PD-L1-expressing
tumor cells.;
Molecule name : FS 222; FS-222;
NCI Metathesaurus CUI : CL1662154;
Origin ID : C179635;
UMLS CUI : C5555830;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
